NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
Shanghai Zhongshan Hospital
Assiut University
Blokhin's Russian Cancer Research Center
Peking University
University of Birmingham
Shandong Cancer Hospital and Institute
Peking University Cancer Hospital & Institute
Fudan University
Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Medical University of Lublin
National Cancer Institute (NCI)